Aktuelles und Veröffentlichungen

Dusseldorf, Germany (Sept. 19, 2023) – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that assist in the early detection of oral cancer, announces the release of its breakthrough product, the BeVigilant OraFusion System, in...

Oral cancer is a steadily growing threat that impacts millions of lives across the world, with nearly half of cases resulting in death.1 Current estimates report that one in 60 men and one in 141 women in the U.S. will develop oral cancer during their lifetimes.2...

A missed cancer diagnosis can be devastating. However, unlike other malignancies, oral cancer is more likely to progress unnoticed until life-threatening stages. This is mainly due to misdiagnosis of early-stage signs and symptoms. One case review found that, among 35...

No matter the type of cancer, an early-stage diagnosis is paramount to ensuring patient survival. For many, the journey to a diagnosis begins with a screening. Cancer screening is not intended to make an official diagnosis; however, these assessments can achieve two...

Despite rapid innovation in cancer diagnostics and treatment, the oral cancer survival rate has yet to improve. Even after 40 years, the average survival rate has not surpassed 50% — an alarming figure spotlighting the need for more impactful diagnostic and treatment...

Historically, oral cancer was thought to be an age-related malignancy; however, the growing prevalence of associated risk factors expands the demographic to younger age groups. This alarming shift brings to light the critical importance of proactive detection...